Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis

PHASE3RecruitingINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

November 30, 2026

Conditions

Prurigo Nodularis

Interventions

DRUG

Placebo

Every four weeks, subcutaneous injection，Switch to MG-K10 treatment after 24 weeks of administration

Trial Locations (1)

RECRUITING

Peking University People's Hospital, Beijing,, Beijing

All Listed Sponsors

lead

Shanghai Mabgeek Biotech.Co.Ltd

OTHER_GOV